Deciphera Pharmaceuticals (DCPH): Q1 GAAP EPS of -$1.06 beats by $0.01.Revenue of $25.2M,beats by $2.15M.Press Release
Deciphera Pharmaceuticals (DCPH): Q4 GAAP EPS of -$1.10 beats by $0.07.Revenue of $19.49M beats by $1.07M.Cash, equivalents and marketable securities were $561.3M.Top-line...
1. AMC Entertainment Holdings (NYSE:AMC) was up 78 cents, or 23%, to 4.14, with a session high of 4.75, on 21.2 million shares traded on Tuesday. It looks to me like the pop out...
Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases. DCC-2618, an orally administered kinase switch control inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, including glioblastoma multiforme (GBM), and other solid tumors driven by pan-KIT or PDGFR alpha. DCC-3014 is an orally administered, potent and highly selective inhibitor of colony stimulating factor receptor 1 (CSF1R). Rebastinib is an orally administered, potent and selective inhibitor of the TIE2 immunokinase. Rebastinib binds potently into the switch pocket of TIE2, stabilizing the inhibitory switch and displacing the activation switch to block TIE2 signaling.